158 related articles for article (PubMed ID: 28463874)
1. Time to transient and stable reductions in hot flush frequency in postmenopausal women using conjugated estrogens/bazedoxifene.
Pinkerton JV; Bushmakin AG; Abraham L; Komm BS; Bobula J
Menopause; 2017 Sep; 24(9):1011-1016. PubMed ID: 28463874
[TBL] [Abstract][Full Text] [Related]
2. Hot flush frequency and severity at baseline as predictors of time to transient and stable treatment success: pooled analysis of two CE/BZA studies.
Pinkerton JV; Bushmakin AG; Bobula J; Lavenberg J; Komm BS; Abraham L
Menopause; 2017 Dec; 24(12):1378-1385. PubMed ID: 28654628
[TBL] [Abstract][Full Text] [Related]
3. Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women.
Yu H; Racketa J; Chines AA; Mirkin S
Climacteric; 2013 Apr; 16(2):252-7. PubMed ID: 23035721
[TBL] [Abstract][Full Text] [Related]
4. Direct and indirect effects of conjugated estrogens/bazedoxifene treatment on quality of life in postmenopausal women.
Abraham L; Bushmakin AG; Dragon E; Komm BS; Pinkerton JV
Maturitas; 2016 Dec; 94():173-179. PubMed ID: 27823739
[TBL] [Abstract][Full Text] [Related]
5. Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials.
Archer DF; Freeman EW; Komm BS; Ryan KA; Yu CR; Mirkin S; Pinkerton JV
J Womens Health (Larchmt); 2016 Nov; 25(11):1102-1111. PubMed ID: 27676118
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of efficacy and safety of conjugated estrogens/bazedoxifene in a Latin American population.
Palacios S; Arias L; Lavenberg J; Pan K; Mirkin S; Komm BS
Climacteric; 2016 Jun; 19(3):261-7. PubMed ID: 26940720
[TBL] [Abstract][Full Text] [Related]
7. Time to first occurrence of breast pain and vaginal bleeding in phase 3 trials of CE/BZA.
Pinkerton JV; Bushmakin AG; Bobula J; Lavenberg J; Komm BS; Abraham L
Menopause; 2017 Dec; 24(12):1372-1377. PubMed ID: 28609389
[TBL] [Abstract][Full Text] [Related]
8. Conjugated estrogens and bazedoxifene in minority populations: pooled analysis of four phase 3 trials.
Pinkerton JV; Pickar JH; Ryan KA; Yu CR; Mirkin S; Komm BS
Menopause; 2016 Jun; 23(6):611-20. PubMed ID: 27163519
[TBL] [Abstract][Full Text] [Related]
9. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.
Pinkerton JV; Utian WH; Constantine GD; Olivier S; Pickar JH
Menopause; 2009; 16(6):1116-24. PubMed ID: 19546826
[TBL] [Abstract][Full Text] [Related]
10. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women.
Utian W; Yu H; Bobula J; Mirkin S; Olivier S; Pickar JH
Maturitas; 2009 Aug; 63(4):329-35. PubMed ID: 19647382
[TBL] [Abstract][Full Text] [Related]
11. Perspective on prescribing conjugated estrogens/bazedoxifene for estrogen-deficiency symptoms of menopause: a practical guide.
Palacios S; Currie H; Mikkola TS; Dragon E
Maturitas; 2015 Apr; 80(4):435-40. PubMed ID: 25684082
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials.
Pinkerton JV; Abraham L; Bushmakin AG; Cappelleri JC; Racketa J; Shi H; Chines AA; Mirkin S
J Womens Health (Larchmt); 2014 Jan; 23(1):18-28. PubMed ID: 24206058
[TBL] [Abstract][Full Text] [Related]
13. The effect of conjugated estrogens/bazedoxifene therapy on body weight of postmenopausal women: pooled analysis of five randomized, placebo-controlled trials.
Black D; Messig M; Yu CR; Assaf AR; Komm BS; Mirkin S; Boucher M
Menopause; 2016 Apr; 23(4):376-82. PubMed ID: 26694733
[TBL] [Abstract][Full Text] [Related]
14. Changes in bone mineral density are correlated with bone markers and reductions in hot flush severity in postmenopausal women treated with bazedoxifene/conjugated estrogens.
Gallagher JC; Shi H; Mirkin S; Chines AA
Menopause; 2013 Nov; 20(11):1126-32. PubMed ID: 23632659
[TBL] [Abstract][Full Text] [Related]
15. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
Parish SJ; Gillespie JA
Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance using mediation modeling.
Pinkerton JV; Bushmakin AG; Racketa J; Cappelleri JC; Chines AA; Mirkin S
Menopause; 2014 Mar; 21(3):243-51. PubMed ID: 23899830
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.
Lobo RA; Pinkerton JV; Gass MLS; Dorin MH; Ronkin S; Pickar JH; Constantine G
Fertil Steril; 2009 Sep; 92(3):1025-1038. PubMed ID: 19635615
[TBL] [Abstract][Full Text] [Related]
18. Tissue-selective estrogen complexes for postmenopausal women.
Mirkin S; Komm BS
Maturitas; 2013 Nov; 76(3):213-20. PubMed ID: 23849704
[TBL] [Abstract][Full Text] [Related]
19. Using bazedoxifene plus conjugated estrogens for treating postmenopausal women: a comprehensive review.
Taylor HS; Ohleth K
Menopause; 2012 Apr; 19(4):479-85. PubMed ID: 22278343
[TBL] [Abstract][Full Text] [Related]
20. Bazedoxifene plus conjugated estrogens improve menopausal symptoms in postmenopausal women: a systematic review and meta-analysis.
Bi B; Jiang Y; Shi Y; Ruan F
Gynecol Endocrinol; 2022 Oct; 38(10):813-821. PubMed ID: 36036169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
